Home › Calculator › HRTX Dividend Calculator 2026
HRTX Dividend Calculator 2026
No dividendHealthcareHeron Therapeutics, Inc. · NASDAQ
Price: $0.30 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
HRTX is not a dividend-focused stock
HRTX pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
HRTX Dividend Yield
Heron Therapeutics, Inc. (HRTX) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When HRTX pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About Heron Therapeutics, Inc. (HRTX) — Dividend Analysis 2026
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
HRTX Dividend & DRIP — Frequently Asked Questions
Does HRTX pay a dividend?
No. Heron Therapeutics, Inc. (HRTX) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of HRTX?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does HRTX have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. HRTX has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to HRTX
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full HRTX DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open HRTX position with:
🌍 HRTX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold HRTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 HRTX Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 HRTX Dividend Payment Schedule
HRTX pays quarterly — 4 times per year. Ex-div: —.
📊 HRTX vs Healthcare Benchmarks
How HRTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for HRTX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ HRTX Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-10-19 | 3,874 | — | — | ||
| F-InKind | 2026-10-19 | 1,102 | $0.36 | $397.00 | ||
| M-Exempt | 2026-10-19 | 3,874 | — | — | ||
| M-Exempt | 2026-10-19 | 3,874 | — | — | ||
| F-InKind | 2026-10-19 | 1,102 | $0.36 | $397.00 | ||
| M-Exempt | 2026-10-19 | 3,874 | — | — | ||
| M-Exempt | 2026-10-19 | 13,797 | — | — | ||
| F-InKind | 2026-10-19 | 3,360 | $0.36 | $1.2K | ||
| M-Exempt | 2026-10-19 | 13,797 | — | — | ||
| M-Exempt | 2026-08-06 | 31,250 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Peer Group
Similar companies in the same sectorCompare HRTX with peers: HRTX vs CHRS · HRTX vs EPRX · HRTX vs GNFT
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the HRTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Heron Therapeutics, Inc. (HRTX) is currently trading at $0.30, 81% below its 52-week high. It does not currently pay a regular dividend.
Does HRTX Pay a Dividend? Heron Therapeutics, Inc. Dividend Status
Heron Therapeutics, Inc. (HRTX) is a healthcare stock trading at $0.30. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest HRTX News
LiveProjected your HRTX DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.